Spots Global Cancer Trial Database for advanced malignant solid tumors
Every month we try and update this database with for advanced malignant solid tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Evaluating TTI-237 in Advanced Malignant Solid Tumors. | NCT00195325 | Tumors Neoplasms | TTI-237 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors | NCT05773937 | Advanced Malign... | 9MW2821 | 18 Years - 80 Years | Mabwell (Shanghai) Bioscience Co., Ltd. | |
| Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors | NCT04226066 | Advanced Malign... | T601 T601+5-FC | 18 Years - 75 Years | Tasly Tianjin Biopharmaceutical Co., Ltd. | |
| A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | NCT01128842 | Advanced Malign... | Neratinib Capecitabine | 20 Years - | Puma Biotechnology, Inc. | |
| Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors | NCT03792958 | Advanced Malign... | CM082 | 18 Years - | AnewPharma | |
| Study Evaluating Safety And Tolerability, Solid Tumor | NCT00768469 | Advanced Malign... | Neratinib Paclitaxel | 20 Years - | Puma Biotechnology, Inc. | |
| The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors | NCT03047811 | Advanced Malign... | TCR - T cell th... | 18 Years - 70 Years | Fudan University | |
| Study Evaluating TTI-237 in Advanced Malignant Solid Tumors | NCT00195247 | Neoplasms | TTI-237 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Study Evaluating MST-997 in Advanced Malignant Solid Tumors | NCT00088647 | Neoplasms | MST-997 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Study Evaluating TTI-237 in Advanced Malignant Solid Tumors. | NCT00195325 | Tumors Neoplasms | TTI-237 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | NCT05277454 | Advanced Malign... TGCT | HMPL-653 | 18 Years - 75 Years | Hutchmed | |
| A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | NCT02045095 | Advanced Malign... | MLN7243 | 18 Years - | Takeda | |
| A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients | NCT00728468 | Advanced Malign... | PF-00299804 | 18 Years - | Pfizer | |
| A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | NCT02045095 | Advanced Malign... | MLN7243 | 18 Years - | Takeda | |
| A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | NCT00445458 | Advanced Breast... Advanced Malign... Breast Neoplasm... | HKI-272 Paclitaxel | 18 Years - | Puma Biotechnology, Inc. | |
| A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors | NCT06231550 | Advanced Malign... | FC084CSA tablet... | 18 Years - 75 Years | FindCure Biosciences (ZhongShan) Co., Ltd. | |
| Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor | NCT05383703 | Advanced Malign... | Treatment of MN... | 18 Years - | Moon (Guangzhou) Biotechnology Co., Ltd. | |
| Using Neoantigen Peptide Vaccine/Neoantigen-based DC to Treat Advanced Malignant Solid Tumors | NCT05749627 | Advanced Malign... | Neoantigen pept... Neoantigen-base... | 18 Years - 70 Years | The First Affiliated Hospital of Nanchang University | |
| A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors | NCT05886374 | Advanced Malign... | HMPL-415S1 | 18 Years - 75 Years | Hutchmed | |
| A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors | NCT05886374 | Advanced Malign... | HMPL-415S1 | 18 Years - 75 Years | Hutchmed | |
| Bioequivalency Study of CM082 Tablet in Healthy Volunteers | NCT04328506 | Advanced Malign... | CM082 tablet (t... CM082 tablet (r... | 18 Years - 45 Years | AnewPharma | |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors | NCT05478785 | Advanced Malign... | Cisplatin micel... | 18 Years - 70 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors | NCT06231550 | Advanced Malign... | FC084CSA tablet... | 18 Years - 75 Years | FindCure Biosciences (ZhongShan) Co., Ltd. | |
| A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors | NCT06231550 | Advanced Malign... | FC084CSA tablet... | 18 Years - 75 Years | FindCure Biosciences (ZhongShan) Co., Ltd. | |
| Bioequivalency Study of CM082 Tablet in Healthy Volunteers | NCT04328506 | Advanced Malign... | CM082 tablet (t... CM082 tablet (r... | 18 Years - 45 Years | AnewPharma | |
| A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers | NCT04126668 | Advanced Malign... | CM082 with fed ... | 18 Years - 45 Years | AnewPharma | |
| Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | NCT05388435 | Advanced Solid ... | SKL27969 | 18 Years - | SK Life Science, Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | NCT05338957 | Advanced Malign... | MRG002+HX008 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | NCT00397046 | Tumors | neratinib | 20 Years - | Puma Biotechnology, Inc. | |
| A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | NCT05338957 | Advanced Malign... | MRG002+HX008 | 18 Years - 75 Years | Shanghai Miracogen Inc. | |
| A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | NCT00397046 | Tumors | neratinib | 20 Years - | Puma Biotechnology, Inc. | |
| Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors | NCT03792958 | Advanced Malign... | CM082 | 18 Years - | AnewPharma | |
| Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | NCT00706030 | Breast Cancer Advanced Malign... | neratinib vinorelbine | 18 Years - | Puma Biotechnology, Inc. | |
| Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | NCT05277454 | Advanced Malign... TGCT | HMPL-653 | 18 Years - 75 Years | Hutchmed | |
| Study of PKI-179 Administered Orally to Subjects With Solid Tumors | NCT00997360 | Advanced Malign... | PKI-179 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Study Evaluating Safety And Tolerability, Solid Tumor | NCT00768469 | Advanced Malign... | Neratinib Paclitaxel | 20 Years - | Puma Biotechnology, Inc. | |
| Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors | NCT00884845 | Advanced Malign... | PM02734 and erl... Erlotinib | 18 Years - | PharmaMar | |
| Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors | NCT05949775 | Advanced Malign... | Neoantigen mRNA... | 18 Years - | Stemirna Therapeutics | |
| A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors | NCT01515306 | Malignant Solid... | ramucirumab (IM... paclitaxel | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
